PMID- 35752824
OWN - NLM
STAT- MEDLINE
DCOM- 20220628
LR  - 20220716
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jun 25
TI  - The prevalence of non-invasive ventilation and long-term oxygen treatment in 
      Helsinki University Hospital area, Finland.
PG  - 248
LID - 10.1186/s12890-022-02044-5 [doi]
LID - 248
AB  - BACKGROUND: Chronic respiratory failure (CRF) can be treated at home with 
      non-invasive ventilation (NIV) and/or long-term oxygen (LTOT). The prevalence of 
      these treatments is largely unknown. We aimed to clarify the prevalence and 
      indications of the treatments, and the three-year mortality of the treated 
      patients in the Helsinki University Hospital (HUH) area in Finland. METHODS: In 
      this retrospective study we analyzed the prevalence of adult CRF patients treated 
      with NIV and/or LTOT on 1.1.2018 and followed these patients until 1.1.2021. Data 
      collected included the underlying diagnosis, patient characteristics, information 
      on treatment initiation and from the last follow-up visit, and mortality during 
      the three-year follow-up. Patients with home invasive mechanical ventilation or 
      sleep apnea were excluded. RESULTS: On 1.1.2018, we had a total of 815 patients 
      treated with NIV and/or LTOT in the Helsinki University Hospital (HUH) area, with 
      a population of 1.4 million. The prevalence of NIV was 35.4 per 100,000, of LTOT 
      24.6 per 100,000 and of the treatments combined 60.0 per 100,000. Almost half, 
      44.5%, were treated with NIV, 41.0% with LTOT, and 14.4% underwent both. The most 
      common diagnostic groups were chronic obstructive pulmonary disease (COPD) 
      (33.3%) and obesity-hypoventilation syndrome (OHS) (26.6%). The three-year 
      mortality in all patients was 45.2%. In the COPD and OHS groups the mortality was 
      61.3% and 21.2%. In NIV treated patients, the treatment durations varied from 
      COPD patients 5.3 years to restrictive chest wall disease patients 11.4 years. 
      The age-adjusted Charlson co-morbidity index (ACCI) median for all patients was 
      3.0. CONCLUSIONS: NIV and LTOT are common treatments in CRF. The prevalence in 
      HUH area was comparable to other western countries. As the ACCI index shows, the 
      treated patients were fragile, with multiple co-morbidities, and their mortality 
      was high. Treatment duration and survival vary greatly depending on the 
      underlying diagnosis.
CI  - (c) 2022. The Author(s).
FAU - Kotanen, Petra
AU  - Kotanen P
AUID- ORCID: 0000-0002-0470-2582
AD  - HUH Heart and Lung Center, University of Helsinki and Helsinki University 
      Hospital, (Haartmaninkatu 4), P.O. Box 372, 00029, Helsinki, Finland. 
      petra.kotanen@hus.fi.
AD  - Doctoral Programme in Clinical Research, University of Helsinki, Helsinki, 
      Finland. petra.kotanen@hus.fi.
FAU - Brander, Pirkko
AU  - Brander P
AD  - HUH Heart and Lung Center, University of Helsinki and Helsinki University 
      Hospital, (Haartmaninkatu 4), P.O. Box 372, 00029, Helsinki, Finland.
FAU - Kreivi, Hanna-Riikka
AU  - Kreivi HR
AD  - HUH Heart and Lung Center, University of Helsinki and Helsinki University 
      Hospital, (Haartmaninkatu 4), P.O. Box 372, 00029, Helsinki, Finland.
LA  - eng
PT  - Journal Article
DEP - 20220625
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - *Acidosis, Respiratory
MH  - Adult
MH  - Finland/epidemiology
MH  - Hospitals
MH  - Humans
MH  - *Noninvasive Ventilation
MH  - *Obesity Hypoventilation Syndrome/therapy
MH  - Oxygen
MH  - Prevalence
MH  - *Pulmonary Disease, Chronic Obstructive/epidemiology/therapy
MH  - Respiration, Artificial
MH  - *Respiratory Insufficiency/epidemiology/therapy
MH  - Retrospective Studies
PMC - PMC9233351
OTO - NOTNLM
OT  - COPD
OT  - Chronic respiratory failure
OT  - Long-term oxygen treatment
OT  - Mortality
OT  - Non-invasive ventilation
OT  - Prevalence
COIS- The authors declare that they have no competing interests.
EDAT- 2022/06/26 06:00
MHDA- 2022/06/29 06:00
PMCR- 2022/06/25
CRDT- 2022/06/25 23:32
PHST- 2022/02/19 00:00 [received]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/06/25 23:32 [entrez]
PHST- 2022/06/26 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
PHST- 2022/06/25 00:00 [pmc-release]
AID - 10.1186/s12890-022-02044-5 [pii]
AID - 2044 [pii]
AID - 10.1186/s12890-022-02044-5 [doi]
PST - epublish
SO  - BMC Pulm Med. 2022 Jun 25;22(1):248. doi: 10.1186/s12890-022-02044-5.